Blood Cancers

Polydatin has relevant preclinical evidence in several blood cancers, including acute myeloid leukaemia and acute lymphoblastic leukaemia.

Overview

The blood-cancer literature focuses on apoptosis, autophagy, cell-cycle effects, and growth suppression.

Acute myeloid leukaemia

• Polydatin inhibits AML tumour growth in vivo in animal work

• Induces cell death through autophagy-related pathways

• Targets survival signalling relevant to leukaemia cell persistence

Acute lymphoblastic leukaemia

• Shows dose-dependent and time-dependent antiproliferative effects in MOLT-4 cells

• Cell-cycle arrest and apoptosis may be potentiated when combined with resveratrol

• Pediatric leukaemia models also show cytotoxic activity

Practical interpretation

This is still preclinical territory, but blood cancers remain one of the meaningful mechanistic areas in the polydatin literature.

References

Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by pyridaben in MOLT-4 leukemia cells
https://www.spandidos-publications.com/10.3892/mmr.2016.4909

Targeting autophagy: polydatin's role in inducing cell death in AML
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1470217/full